1 – 10 of 10
      - show: 10
- |
- sort: year (new to old)
        Close
        
            
    
    Embed this list
<iframe src=""
              width=""
              height=""
              allowtransparency="true"
              frameborder="0">
            </iframe>
        - 2019
- 
                        Mark
        BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer
    (2019) In Clinical cancer research : an official journal of the American Association for Cancer Research 25(23). p.7139-7150- Contribution to journal › Article
 
- 2018
- 
                        Mark
        Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancer
    
    - Contribution to journal › Article
 
- 2017
- 
                        Mark
        Therapeutic rationale to target highly expressed CDK7 conferring poor outcomes in triple-negative breast cancer
    
    - Contribution to journal › Article
 
- 2016
- 
                        Mark
        Targeted MS Assay Predicting Tamoxifen Resistance in Estrogen-Receptor-Positive Breast Cancer Tissues and Sera
    
    - Contribution to journal › Article
 
- 
                        Mark
        Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer
    
    - Contribution to journal › Article
 
- 
                        Mark
        4-protein signature predicting tamoxifen treatment outcome in recurrent breast cancer
    
    - Contribution to journal › Article
 
- 
                        Mark
        Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.
    
    - Contribution to journal › Article
 
- 2015
- 
                        Mark
        BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential.
    
    - Contribution to journal › Article
 
- 2011
- 
                        Mark
        PKA-induced phosphorylation of ER alpha at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer
    
    - Contribution to journal › Article
 
- 2009
- 
                        Mark
        Estrogen Receptor-{alpha} Phosphorylation at Serine-118 and Tamoxifen Response in Breast Cancer.
    
    - Contribution to journal › Article